TNO155 (Not yet branded)

Other Medications

US Experimental EU Experimental ES Not available Oral 5 Clinical Trials
SHP2

Description

TNO155 is a small molecule inhibitor of SHP2 (Src homology 2 domain-containing protein tyrosine phosphatase 2) being evaluated in combination therapies for colorectal cancer. This compound targets tumors harboring BRAF V600E mutations and KRAS mutations, which are common driver mutations in colorectal cancer that lead to resistance to standard therapies. TNO155 has been studied in combination with KRAS G12C inhibitors like adagrasib, as well as with immunotherapy agents and CDK4/6 inhibitors in patients with advanced or metastatic disease.

Mechanism of Action

TNO155 inhibits SHP2, a protein tyrosine phosphatase that plays a critical role in multiple oncogenic signaling pathways including RAS/MAPK, PI3K/AKT, and JAK/STAT pathways. By blocking SHP2 function, TNO155 disrupts these growth-promoting signals that are often hyperactivated in BRAF and KRAS mutant tumors. This mechanism makes SHP2 inhibition an attractive approach for overcoming resistance to targeted therapies in RAS pathway-driven cancers.

Molecular Targets

Side Effects

Diarrhea Fatigue Nausea Decreased appetite Skin rash Elevated liver enzymes Thrombocytopenia Anemia

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04699188 Phase 1
Active, not recruiting
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
United States, Australia, Belgium, Canada, China, Denmark, France, Germany, Hong
NCT04294160 Phase 1
Terminated
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
United States, Australia, Belgium, Canada, Germany, Israel, Netherlands, Singapo
NCT04330664 Phase 1
Completed
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
United States
NCT04185883 Phase 1
Active, not recruiting
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
United States, Australia, Austria, Belgium, Canada, Germany, Italy, Japan, Nethe
NCT04000529 Phase 1
Archived
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
United States, Australia, Belgium, China, Germany, Hong Kong, Japan, Singapore,

Quick Info

Brand NameNot yet branded
CategoryOther Medications
US StatusExperimental
EU EMA StatusExperimental
ES Spain AccessNot available
AdministrationOral
Clinical Trials5
View Clinical Trials Back to Drug Glossary

Related Medications

Rmc-4630
Other Medications
2 trials
Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.